<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174300</url>
  </required_header>
  <id_info>
    <org_study_id>UCV/2018-2019/076</org_study_id>
    <nct_id>NCT04174300</nct_id>
  </id_info>
  <brief_title>Molecular Response to Custom Manual Physiotherapy Treatment of Fibromyalgia &amp; Chronic Fatigue Syndrome (CFS)</brief_title>
  <official_title>Molecular Response to Custom Manual Physiotherapy Treatment of Fibromyalgia &amp; Chronic Fatigue Syndrome (CFS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Universidad Católica de Valencia San Vicente Mártir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Universidad Católica de Valencia San Vicente Mártir</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibromyalgia (FM)and Chronic Fatigue Syndrome (CFS) are complex diseases often presenting&#xD;
      overlapping symptomatology. Manual therapy (MT) protocols report benefits for pain treatment&#xD;
      of FM, but the underlying mechanisms for patient improvement remain unknown.&#xD;
&#xD;
      The main goal of this study is to assess the molecular changes associating to mechanical and&#xD;
      additional MT triggers, possibly involved in patient symptom improvement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Fibromyalgia as primary diagnosis assessed by the 1990 &amp; 2010 ACR (American&#xD;
      College of Rheumatology) criteria, presenting or not comorbid CFS, according to the Canadian&#xD;
      and International CFS criteria, age 40-75 and BMI&lt;35 (N=40), will be subjected to&#xD;
      physiotherapy treatment consisting on 8 sessions of manual therapy (twice weekly) of 25&#xD;
      minutes including pressure maneuvers of about 4,5 N by a single operator (Collegiate&#xD;
      Physiotherapist). Blood samples (10-20mls/participant) will be obtained before and after&#xD;
      first treatment, and after fourth and last treatment to determine molecular blood changes&#xD;
      associated to the physiotherapy protocol applied. PBMC (Peripheral Blood Molecular Cells)&#xD;
      transcriptome before and after treatments (RNAseq) will be studied towards identifying&#xD;
      treatment-associated differential expression, mechanomiR profiles included. Patient health&#xD;
      status with treatment will be monitored by FIQ, MFI and SF-36 questionnaires, in addition to&#xD;
      an anonymized satisfaction questionnaire to register potential undesired secondary effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Actual">March 10, 2020</completion_date>
  <primary_completion_date type="Actual">March 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Outcome measures will be randomized and anonymized</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue score</measure>
    <time_frame>8 weeks</time_frame>
    <description>MFI, 1-5 scale (20 items), higher scores indicate higher degree of fatigue</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain index</measure>
    <time_frame>8 weeks</time_frame>
    <description>FIQ and Visual analogue scale (VAS) of pain, Scale 0-100, &lt;39 mild, 39-58 moderate, ≥59 severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differential gene expression</measure>
    <time_frame>8 weeks</time_frame>
    <description>RNAseq</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>8 weeks</time_frame>
    <description>SF-36, 0-100 Likert scale (36 items), lower scores indicate poorer quality of health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANS (autonomic nervous system) dysfunction</measure>
    <time_frame>8 weeks</time_frame>
    <description>Plantar pressure maps</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subjective response to treatment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Custom-made questionnaire, -1 to +1 scale (ítems 1-5), scale 1-10 (item 6), 6 items total, higher scores indicate improvement of symptoms</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Fibromyalgia (FM)</condition>
  <condition>Chronic Fatigue Syndrome (CFS)</condition>
  <arm_group>
    <arm_group_label>Manual Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Manual Therapy</intervention_name>
    <description>8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N</description>
    <arm_group_label>Manual Therapy</arm_group_label>
    <other_name>Physiotherapy treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of FM with or without comorbid CFS&#xD;
&#xD;
          -  Not receiving hormone therapy&#xD;
&#xD;
          -  Not suffering from other diseases&#xD;
&#xD;
          -  Without previous history of cancer&#xD;
&#xD;
          -  Not actively participating in any pharmacological trial&#xD;
&#xD;
          -  Not taking medication for at least 12 hours before blood draw&#xD;
&#xD;
          -  Having signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Any uncompliance with what is described as inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Garcia-Escudero, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Católica de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisa Oltra, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad Católica de Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinicas Universitarias UCV</name>
      <address>
        <city>Valencia</city>
        <zip>46001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.ucv.es/investigacion/grupos-de-investigacion/grupoclave/1431</url>
    <description>UCV Physiotherapy Research Group</description>
  </link>
  <reference>
    <citation>Espejo JA, García-Escudero M, Oltra E. Unraveling the Molecular Determinants of Manual Therapy: An Approach to Integrative Therapeutics for the Treatment of Fibromyalgia and Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Int J Mol Sci. 2018 Sep 9;19(9). pii: E2673. doi: 10.3390/ijms19092673. Review.</citation>
    <PMID>30205597</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Universidad Católica de Valencia San Vicente Mártir</investigator_affiliation>
    <investigator_full_name>María García Escudero</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Manual Therapy</keyword>
  <keyword>Physiotherapy</keyword>
  <keyword>Fibromyalgia (FM)</keyword>
  <keyword>Chronic Fatigue Syndrome (CFS)</keyword>
  <keyword>RNAseq</keyword>
  <keyword>microRNA</keyword>
  <keyword>mechanomiR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

